Business
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 I...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n \n \n Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020\n \n \n \n \n \n \n Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using Vascepa loading dose\n \n \n \n \n \n \n Vascepa administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care group\n \n \n \n \n \n \n Larger follow-on clinical studies have commenced of Vascepa as a therapeutic option in COVID-19 settings, anticipated to be completed in 2021\n \n \n \n \n \n \n TORONTO\n \n ,\n \n Dec. 14, 2020\n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, today announced the presentation of clinical results from the CardioLink-9 Trial, the first results of a study of Vascepa® (icosapent ethyl) in COVID-19 infected outpatients. The presentation,\n \n \"First Human Trial of a Loading Dose of Icosapent Ethyl in Patients with COVID-19: Primary Results of the Vascepa COVID-19 CardioLink-9 Randomized Trial\"\n \n , was made virtually as a Late Breaker at the National Lipid Association (\"NLA\") Scientific Sessions 2020, and was presented on behalf of all authors by\n \n Deepak L. Bhatt\n \n , M.D., M.P.H.,\n \n Brigham\n \n and Women's Hospital,\n \n Harvard Medical School\n \n ,\n \n Boston, MA.\n \n \n \n \"In the current environment, most COVID-19 positive patients remain outside of the clinical setting, following the advice of their doctor to stay home and quarantine unless absolutely necessary to enter ...